Fox Run Management L.L.C. bought a new position in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) during the second quarter, Holdings Channel reports. The institutional investor bought 30,100 shares of the biotechnology company’s stock, valued at approximately $417,000.

A number of other large investors also recently made changes to their positions in the stock. State Street Corp increased its stake in shares of Heron Therapeutics by 24.6% in the fourth quarter. State Street Corp now owns 1,367,565 shares of the biotechnology company’s stock worth $17,913,000 after buying an additional 270,022 shares in the last quarter. Guggenheim Capital LLC increased its stake in shares of Heron Therapeutics by 10.1% in the fourth quarter. Guggenheim Capital LLC now owns 102,069 shares of the biotechnology company’s stock worth $1,337,000 after buying an additional 9,339 shares in the last quarter. Teachers Advisors LLC increased its stake in shares of Heron Therapeutics by 3.4% in the fourth quarter. Teachers Advisors LLC now owns 57,858 shares of the biotechnology company’s stock worth $758,000 after buying an additional 1,924 shares in the last quarter. Highbridge Capital Management LLC increased its stake in shares of Heron Therapeutics by 1.6% in the fourth quarter. Highbridge Capital Management LLC now owns 15,697 shares of the biotechnology company’s stock worth $206,000 after buying an additional 252 shares in the last quarter. Finally, Nationwide Fund Advisors increased its stake in shares of Heron Therapeutics by 11.3% in the first quarter. Nationwide Fund Advisors now owns 21,972 shares of the biotechnology company’s stock worth $330,000 after buying an additional 2,233 shares in the last quarter.

Heron Therapeutics, Inc. (HRTX) opened at 15.45 on Monday. Heron Therapeutics, Inc. has a 52 week low of $12.21 and a 52 week high of $24.00. The company’s 50 day moving average price is $14.19 and its 200-day moving average price is $14.10.

Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings data on Wednesday, May 10th. The biotechnology company reported ($1.00) EPS for the quarter, missing the consensus estimate of ($0.94) by $0.06. The business had revenue of $3.63 million during the quarter, compared to the consensus estimate of $1.96 million. On average, analysts expect that Heron Therapeutics, Inc. will post ($3.73) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Fox Run Management L.L.C. Takes Position in Heron Therapeutics, Inc. (NASDAQ:HRTX)” was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another domain, it was copied illegally and republished in violation of United States & international copyright & trademark law. The correct version of this piece can be accessed at https://www.watchlistnews.com/fox-run-management-l-l-c-takes-position-in-heron-therapeutics-inc-nasdaqhrtx/1444573.html.

HRTX has been the topic of a number of recent analyst reports. Aegis reaffirmed a “buy” rating on shares of Heron Therapeutics in a research note on Tuesday, March 21st. Jefferies Group LLC reiterated a “buy” rating and set a $29.00 price target on shares of Heron Therapeutics in a research report on Monday, April 10th. Zacks Investment Research cut shares of Heron Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, May 9th. Cantor Fitzgerald reiterated a “buy” rating and set a $31.00 price target (up from $30.00) on shares of Heron Therapeutics in a research report on Thursday, May 11th. Finally, Noble Financial reiterated a “buy” rating on shares of Heron Therapeutics in a research report on Friday, May 12th. One equities research analyst has rated the stock with a sell rating and eleven have issued a buy rating to the stock. Heron Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $31.89.

In related news, VP Kimberly Manhard sold 21,542 shares of Heron Therapeutics stock in a transaction that occurred on Monday, April 24th. The stock was sold at an average price of $15.33, for a total transaction of $330,238.86. Following the transaction, the vice president now owns 5,250 shares in the company, valued at $80,482.50. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 20.31% of the company’s stock.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Want to see what other hedge funds are holding HRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heron Therapeutics, Inc. (NASDAQ:HRTX).

Institutional Ownership by Quarter for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.